乳腺癌组织中c-erbB-2 p53 PCNA及bcl-2蛋白的表达及其临床意义  

The Expression of c-erbB-2, p53, PCNA and bcl-2 in Breast Cancer and Its Clinical Significance

作　　者：陆海波[1] 王东亮[1] 张清媛[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院内八科,哈尔滨市150040

出　　处：《中国肿瘤临床》2009年第21期1232-1234,共3页Chinese Journal of Clinical Oncology

基　　金：黑龙江省卫生厅医学科研基金项目资助(编号:2005-061)

摘　　要：目的:探讨生物学指标c-erbB-2、p53、PCNA及bcl-2在乳腺癌中的表达与乳腺癌病理生物学行为的关系。方法:应用免疫组织化学方法对56例乳腺癌组织切片c-erbB-2、p53、PCNA及bcl-2的表达进行检测。结果:c-erbB-2表达41.1%,与组织学分级呈正相关,与临床分期、病理类型、患者年龄(≥35岁)、ER、PR受体关系不密切;p53蛋白表达48.2%,与组织学分级、ER、PR受体呈正相关,与患者年龄(≥35岁)、临床分期、病理类型呈负相关;全组PCNA表达100%;bcl-2表达50.0%,与组织学分级、病理类型、ER、PR受体呈负相关,与临床分期呈正相关,与患者年龄(≥35岁)关系不密切。结论:生物学指标c-erbB-2、p53、PCNA及bcl-2应与临床预后因素临床期别、组织学分级等联合应用,提高对乳腺癌预后评价的正确性。Objective： To detect the correlation of the expression of c-erbB-2, p53, PCNA and bcl-2 with the biological behavior of breast cancer. Methods： We used immunohistochemistry to detect the expression of c-erbB-2, p53, PCNA and bcl-2 in 56 breast cancer patients. Results： The expression of c-erbB-2 was 41.1% and was negatively correlated with histological classification but was not correlated with age, clinical stage, ER, or PR. The expression of p53 was 48.2% and was positively related with ER and PR but was negatively correlated with clinical stage and pathological type. The expression of bcl-2 was 50.0% and was negatively correlated with histological classification, ER and PR and was positively correlated with clinical stage and pathological type. PCNA was highly expressed in the 56 cases. Conclusion： We should combine the detection of c-erbB-2, p53, PCNA and bcl-2 with the evaluation of clinical stage, histological degree and pathological type in order to improve the prognostic estimation of breast cancer.

关 键 词：乳腺癌 免疫组织化学 癌基因 基因表达 

分 类 号：R737.9[医药卫生—肿瘤]